(Q46350665)

English

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

scientific article published in October 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers (English)

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

S Hüttner

1

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

E U Graefe-Mody

2

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

B Withopf

3

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

A Ring

4

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

A Ring

5

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

K A Dugi

6

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

publication date

1 October 2008

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

48

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

10

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

1171-1178

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Diagnosis and classification of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Therapeutic strategies based on glucagon-like peptide 1.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Clinical pharmacokinetics of ramipril

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Prevalence of kidney damage in Australian adults: The AusDiab kidney study.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323753

21 January 2018

Identifiers

10.1177/0091270008323753

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18812608

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46350665&oldid=2143928901"